BAC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Bank of America Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Bank of America Corporation · Financial Services
$53.95
-41.2% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
BAC trades at a lower forward P/E
(12.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BAC |
PFE |
| Current Price |
$53.95 |
$26.33 |
| Fair Value Estimate |
$31.74 |
$33.85 |
| Upside to Fair Value |
-41.2%
|
+28.6%
|
| Market Cap |
$387.2B |
$149.8B |
| Forward P/E |
12.3x
|
19.3x
|
| EV / EBITDA |
12.7x
|
12.9x
|
| Price / Sales |
2.2x
|
2.4x
|
| Price / FCF |
30.7x
|
16.5x
|
| Revenue Growth YoY |
-35.6%
|
-1.2%
|
| Gross Margin |
63.2%
|
70.3%
|
| Operating Margin |
22.9%
|
24.7%
|
| Return on Equity |
10.5%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.26%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Bank of America Corporation is a leading diversified bank with $3.41 trillion in assets and a broad footprint across consumer banking, global markets, wealth management, and corporate banking. The company benefits from a strong market position and experienced leadership under CEO Brian T. Moynihan. However, the stock is currently overvalued, trading approximately 36% above its fair value estimate…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
BAC |
PFE |
| Zone Low |
$23.80 |
$25.39 |
| Zone High |
$26.98 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|